Public Companies
Akeso's Lung Cancer Drug Posts Survival Gains, Putting Pressure on Established Therapies
Trial data for ivonescimab suggest the bispecific antibody may outperform a leading checkpoint inhibitor in certain non-small cell lung cancer patients — a result with meaningful commercial implications.